Drug Database
DO

doxycycline (Perio Product / Atridox / doxycycline, Atrix)

✓ Approved

Pharmascience, Inc. · Small Molecule · Small Molecule

What is doxycycline?

doxycycline is a small molecule developed by Pharmascience, Inc.. It is approved for therapeutic indications via oral (po) or topical.

Drug Profile

Brand NamesPerio Product, Atridox, doxycycline, Atrix
CompanyPharmascience, Inc.
Drug ClassSmall Molecule
RouteOral (PO), Topical
StatusApproved
Sources: ClinicalTrials.gov, Pharmascience, Inc.

Therapeutic Indications

doxycycline is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsPeriodontitis✓ Approved

Related Research Articles

PubMedItalian journal of food safety2026-10-15

Assessment of antibiotic residues and microbiological safety in Lebanese dairy products: Akkawi cheese, yogurt, and labneh, collected across Lebanese dairy industries.

Joubrane Karine K, Daher Zeina Z, Jammoul Adla A, Chahrour Jamil Atef JA et al.

Antibiotic residues in dairy products and the resulting antibiotic-resistant bacteria represent a major global public health concern. This study evaluated the microbiological safety of 400 dairy samples collected over two consecutive years (2022 and 2023) from 16 dairy residue industries across four governorates in Lebanon. In addition, antibiotic residues were screened from 126 dairy product samples randomly chosen out of the 400. An optimized multi-class method for the identification and quantification of 30 antibiotics was developed using liquid chromatography-mass spectrometry. Results revealed that 48% of the analyzed samples were contaminated with at least one antibiotic residue, among which 33% showed co-occurrence of multiple antibiotic classes. Meanwhile, microbiological assessment of 400 dairy samples collected over 2 years from the same dairies revealed higher levels of contamination with total coliforms, Escherichia coli, and Staphylococcus aureus in Akkawi cheese samples collected during the first year (44%, 32%, and 15%, respectively) compared to those collected the second year (38.8%, 31%, and 0%). Moderate contamination levels were observed in Labneh (strained yogurt) samples collected during both seasons, with yeast (12%; 11%), molds (1.2%; 11%), total coliforms (6%; 11%), and Escherichia coli (3.7%; 11%). On the other hand, comparable levels of non-conformity were observed in yogurt samples across the two years, with contamination by yeast (7.5%; 6.2%), molds (3.75%; 6.2%), total coliforms (26%; 31.2%), E. coli (20%; 21%), and Staphylococcus aureus (1.25%; 0%). Escherichia coli isolates exhibited resistance to tetracycline while being 100% sensitive to ciprofloxacin and nalidixic acid. As for S. aureus isolates, they presented a high sensitivity to tetracyclines, doxycycline, and ciprofloxacin. These findings highlight the importance of implementing and maintaining good hygienic practices within dairy industries. Antimicrobial residues of oxytetracycline, tetracycline, ciprofloxacin, sulfamethazine, and doxycycline were detected at levels below the maximum residue limits.

PMID 42876308
Read full article →
PubMedIDCases2026-10-14

Development of bilateral facial nerve palsies while receiving doxycycline for early disseminated Lyme disease.

Chang Bickey H BH, Nussenblatt Veronique R VR, Goldberg Joel A JA, Hamie Mohamed M et al.

Disease progression is uncommon in patients diagnosed with Lyme disease who receive appropriate therapy. Here we report a case of a patient developing bilateral facial nerve palsies while receiving oral doxycycline therapy for early disseminated Lyme disease and review the literature of similar cases. A 58-year-old previously healthy male from the mid-Atlantic area in the U.S. presented with a multifocal erythematous rash consistent with erythema migrans after international travel. His clinical presentation and two-step Lyme-serology testing confirmed a diagnosis of Lyme disease. Four days into initiation of doxycycline therapy, he developed bilateral facial weakness including difficulty raising the corners of his mouth and lifting his eyebrows bilaterally. He experienced neurologic improvement with ongoing antimicrobial therapy with ceftriaxone and subsequent doxycycline and had complete recovery 7 weeks later. This case describes an uncommon presentation of neuroborreliosis with bilateral facial palsies which developed after initiation of treatment of early disseminated Lyme disease. The manifestations in this case may be due to host immune reaction as seen in other spirochetal diseases. The findings resolved with continued therapy. In our review of the literature, we identified three additional cases of neuroborreliosis which progressed on treatment but also had eventual resolution of signs and symptoms. Clinicians should be aware that facial palsies rarely can occur on therapy for Lyme disease but do not necessarily imply a worse prognosis.

PMID 42871197
Read full article →
PubMedJournal of infection and public health2026-10-14

Does macrolide resistance play a role in the clinical outcome of patients with Mycoplasma pneumoniae infection?

Stefan Marek M, Sindlerova Renata R, Dratvova Barbora B, Fila Libor L et al.

A marked increase in Mycoplasma pneumoniae infections was observed across Europe in 2023, while data on resistance to macrolides, the recommended first-line therapy, remained limited. This study assessed the prevalence of macrolide-resistant M. pneumoniae (MRMP) and its impact on clinical outcomes. Patients diagnosed with M. pneumoniae infection by multiplex PCR between January 2024 and January 2025 were included. Macrolide-resistance mutations were retrospectively identified by PCR and Sanger sequencing of domain V of the 23S rRNA gene. Clinical characteristics, treatment without results on the macrolide-resistant genotype, and outcomes were analysed. Among 373 PCR-positive cases (155 children, 218 adults), resistance genotype and outcome data were available for 179 patients. Overall MRMP prevalence was 21.2%, decreasing from 28.9% to 18.7% between study periods (p = 0.21). The most common mutation was A2063G (86.8%), followed by A2064G (10.5%) and A2064C (2.6%). The median time from symptom onset to diagnosis was 8 days, and 57.5% of patients were hospitalised. No significant differences were detected between MRMP and macrolide-susceptible M. pneumoniae (MSMP) infections in clinical characteristics, hospitalisation rates, or doxycycline use. Defervescence after macrolide therapy was numerically longer in MRMP than in MSMP infections, although the difference was not statistically significant (median 4 vs 2.5 days, p = 0.13). MRMP was common but had limited impact on overall clinical outcomes, possibly reflecting the frequent doxycycline use. Macrolide resistance showed a non-significant trend towards delayed defervescence. Our findings suggest that doxycycline may represent a treatment option in complicated cases when susceptibility is unknown, but prospective studies are needed to determine its clinical effectiveness.

PMID 42874427
Read full article →
PubMedJournal of tropical pediatrics2026-10-14

Clinical and biochemical determinants of critical deterioration in paediatric scrub typhus: a retrospective study from a tertiary care centre in South India.

Hari Prasath C C, Kumar P Anil PA, Sripooja Penatal P

Scrub typhus causes substantial morbidity and mortality in children across South Asia, yet admission-time predictors of critical deterioration remain poorly characterized in the paediatric population. This study aimed to identify independent predictors of critical deterioration in hospitalized children with confirmed scrub typhus. A retrospective observational cohort study was conducted at a tertiary-care teaching hospital in South India over 6 years. Children aged 1-14 years with immunoglobulin M enzyme-linked immunosorbent assay-confirmed scrub typhus were included. Critical deterioration, a pre-specified composite of shock, acute respiratory distress syndrome, multiple organ dysfunction syndrome, mortality, or high-flow respiratory support requirement, constituted the primary outcome. Independent predictors were identified by multivariable logistic regression, and discriminatory performance was assessed by area under the receiver operating characteristic curve (AUROC). One hundred and eighty-one children were enrolled (median age 6.0 years; 50.3% male). Critical deterioration occurred in 62 children (34.3%), with a case fatality rate of 12.9% among those affected. Serum albumin demonstrated the highest univariable discriminatory performance (AUROC 0.973), followed by neutrophil-to-lymphocyte ratio (NLR) (0.945), total bilirubin (0.929), and lactate dehydrogenase (0.902). Four variables independently predicted critical deterioration on multivariable analysis: NLR [adjusted odds ratio (aOR) 3.811, 95% confidence interval (CI): 2.119-6.857; P < .001), C-reactive protein (CRP) (aOR 1.052, 95% CI: 1.018-1.089; P = .003), doxycycline delay (aOR 1.829, 95% CI: 1.146-2.920; P = .011), and serum sodium (aOR 0.689, 95% CI: 0.523-0.909; P = .008). The model demonstrated excellent discrimination (apparent AUROC 0.986, 95% CI: 0.971-0.997; optimism-corrected AUROC 0.982, 95% CI: 0.978-0.987) and satisfactory calibration (Hosmer-Lemeshow P = .997). NLR, CRP, serum sodium, and doxycycline delay independently predict critical deterioration in paediatric scrub typhus at hospital admission, with serum albumin demonstrating the highest univariable discriminatory performance. Serial biomarker trajectories demonstrated sustained inflammatory and haemodynamic perturbation through 72 hours in deteriorating children, in contrast to the rapid biochemical resolution observed in those who recovered. These findings require external prospective validation before application to clinical risk stratification.

PMID 42875176
Read full article →
PubMedRSC advances2026-10-14

CoAl2O4/Co3O4/boron and nitrogen doped biochar for round-the-clock ultra-efficient degradation of 4-nitrophenol with peroxymonosulfate.

Guo Haoran H, Xu Zixuan Z, Ding Xiaoli X, Li He H et al.

Developing a new strategy to boost the degradation efficiency of photocatalysts for toxic phenolic compounds in peroxymonosulfate (PMS)-based degradation processes was essential but remained an challenging task. Our study proposed the one-pot construction of CoAl2O4/Co3O4/boron and nitrogen doped biochar (CoAl2O4/Co3O4/BNC) to accelerate the PMS activation and enable ultra-fast degradation of 80 mg L-1 nitrophenol (4-NiP). Radical species (˙OH, SO4˙-, and h+) and non-radical (1O2) played crucial roles during the degradation process. Additionally, 4-NiP was effectively degraded across the full pH range. The catalyst's stability in simulated real aqueous environments was evaluated, demonstrating that the CoAl2O4/Co3O4/BNC exhibited excellent recyclability and anti-interference capability during degradation. Under UV-visible light irradiation, 80 mg L-1 of 4-NiP was degraded within 10 min, it has been demonstrated that illumination accelerates the activation of PMS and the photocatalytic degradation rate of 4-NiP. Furthermore, the degradation efficiency exceeded 95% for seven types of organic pollutants in different water matrices. Seven types of organic pollutants included levofloxacin (LEV), tetracycline (TC), doxycycline hydrochloride (DOX), ciprofloxacin (CIP), 2-chloro-4-nitrophenol (2C4Nip), 2-chloro-6-nitrophenol (2C6Nip), these results confirmed the capability of CoAl2O4/Co3O4/BNC to activate PMS for degrading organic pollutants in wastewater.

PMID 42872095
Read full article →
PubMedFrontiers in medicine2026-10-14

Q fever with biliary dilatation following contact with muntjac deer: a case report.

Mao Wulong W, Yang Yuping Y, Yu Xinghao X, Wu Chenxi C et al.

Q fever is a zoonosis caused by Coxiella burnetii. Classic presentations include atypical pneumonia and hepatitis, but bile duct dilation on imaging is rarely described. We report a case of acute Q fever in an urban resident of Chengdu, Sichuan Province, Southwestern China, who presented with cholestatic liver injury and intra- and extrahepatic bile duct dilation, highlighting an unusual manifestation that mimicked biliary tract disease. A 53-year-old man was admitted with persistent high fever (up to 41.8 °C), headache, chills, and right upper quadrant pain. Laboratory tests showed cholestatic hepatitis (AST 132 U/L, ALT 110 U/L, ALP 221 U/L, GGT 231 U/L), with normal total and direct bilirubin. Magnetic resonance cholangiopancreatography (MRCP) revealed mild intra- and extrahepatic bile duct dilation without obstruction. The patient had no livestock contact but had been exposed to wild muntjac deer from informal sources. Empiric doxycycline combined with piperacillin-tazobactam led to rapid defervescence and symptom improvement. The diagnosis of acute Q fever was supported by metagenomic next-generation sequencing (mNGS) of peripheral blood, in the absence of confirmatory seroconversion. In this case, bile duct dilation without jaundice was a notable manifestation of the infection. For febrile patients with unexplained cholestasis and bile duct dilation, especially those with a history of contact with wild animals, Q fever should be considered in the differential diagnosis.

PMID 42871002
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about doxycycline